Indoco Remedies Ltd
Indoco Remedies Ltd Share Price Today: Live Updates & Key Insights
Get insights on Indoco Remedies Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Indoco Remedies Ltd Share Price Chart
Indoco Remedies Ltd Fundamentals
Traded Volume: 60,235
Market Cap(Cr): 2,373
Avg Traded Price 257.05
1 Year return -14.19%
Upper Circuit 261.9
Lower Circuit 251.7
P/E TTM -21.00
P/B Ratio -12.00
Traded Value(Cr) 154.95
EPS TTM -11.979
Book value -11.979
Dividend 0.00%
Indoco Remedies Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Indoco Remedies Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Indoco Remedies Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W -3.74%
1M -10.30%
3M -9.13%
1Y -14.19%
YTD -24.13%
Indoco Remedies Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Indoco Remedies Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 66213.00
Day Before Yesterday 34135.00
1W Avg 47203.80
1M Avg 67211.81
3M Avg 1.66L
Indoco Remedies Ltd Technical Details
Indoco Remedies Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 null
Support 2 null
Support 3 null
Pivot Point : null
Resistance 1 null
Resistance 2 null
Resistance 3 null
Indoco Remedies Ltd Corporate Actions
Indoco Remedies Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Indoco Remedies Ltd’s capital allocation strategies.
All
Ex-Date 04-Sep-2025 Type D Description 0.20/share@10.00% Record Date 04-Sep-2025 Ratio 10.00
Ex-Date 19-Sep-2024 Type D Description 1.50/share@75.00% Record Date 19-Sep-2024 Ratio 75.00
Ex-Date 18-Sep-2023 Type D Description 2.25/share@112.50% Record Date 19-Sep-2023 Ratio 112.50
Ex-Date 14-Sep-2022 Type D Description 0.75/share@37.50% Record Date - Ratio 37.50
Ex-Date 14-Sep-2022 Type D Description 1.50/share@75.00% Record Date 15-Sep-2022 Ratio 75.00
Ex-Date 17-Sep-2021 Type D Description 1.50/share@75.00% Record Date - Ratio 75.00
Ex-Date 18-Sep-2020 Type D Description 0.30/share@15.00% Record Date - Ratio 15.00
Ex-Date 22-Aug-2019 Type D Description 0.30/share@15.00% Record Date - Ratio 15.00
Ex-Date 31-Aug-2018 Type D Description 1.00/share@50.00% Record Date - Ratio 50.00
Ex-Date 31-Jul-2017 Type D Description 1.60/share@80.00% Record Date - Ratio 80.00
Ex-Date 20-Jul-2016 Type D Description 0.20/share@10.00% Record Date - Ratio 10.00
Ex-Date 17-Mar-2016 Type D Description 1.40/share@70.00% Record Date 18-Mar-2016 Ratio 70.00
Ex-Date 21-Jul-2015 Type D Description 1.60/share@80.00% Record Date - Ratio 80.00
Ex-Date 21-Jul-2014 Type D Description 1.40/share@70.00% Record Date - Ratio 70.00
Ex-Date 19-Jul-2013 Type D Description 1.10/share@55.00% Record Date - Ratio 55.00
Ex-Date 20-Jul-2012 Type D Description 1.10/share@55.00% Record Date - Ratio 55.00
Ex-Date 17-May-2012 Type B Description share@1:2 Record Date 17-May-2012 Ratio 1:2
Ex-Date 17-May-2012 Type S Description share@1:5.00 Record Date 19-May-2012 Ratio 1:5.00
Ex-Date 19-Jul-2011 Type D Description 8.00/share@80.00% Record Date - Ratio 80.00
Ex-Date 13-Jul-2010 Type D Description 7.00/share@70.00% Record Date - Ratio 70.00
Ex-Date 09-Sep-2009 Type D Description 2.00/share@20.00% Record Date - Ratio 20.00
Ex-Date 11-Dec-2008 Type D Description 3.25/share@32.50% Record Date 12-Dec-2008 Ratio 32.50
Ex-Date 19-Sep-2008 Type D Description 5.00/share@50.00% Record Date - Ratio 50.00
Ex-Date 13-Dec-2007 Type D Description 6.50/share@65.00% Record Date - Ratio 65.00
Dividends
Announcement Date 04-Sep-2025 Ex Dividend Date 04-Sep-2025 Dividend(%) 10
Announcement Date 19-Sep-2024 Ex Dividend Date 19-Sep-2024 Dividend(%) 75
Announcement Date 18-Sep-2023 Ex Dividend Date 18-Sep-2023 Dividend(%) 113
Announcement Date 14-Sep-2022 Ex Dividend Date 14-Sep-2022 Dividend(%) 38
Announcement Date 14-Sep-2022 Ex Dividend Date 14-Sep-2022 Dividend(%) 75
Announcement Date 17-Sep-2021 Ex Dividend Date 17-Sep-2021 Dividend(%) 75
Announcement Date 18-Sep-2020 Ex Dividend Date 18-Sep-2020 Dividend(%) 15
Announcement Date 22-Aug-2019 Ex Dividend Date 22-Aug-2019 Dividend(%) 15
Announcement Date 31-Aug-2018 Ex Dividend Date 31-Aug-2018 Dividend(%) 50
Announcement Date 31-Jul-2017 Ex Dividend Date 31-Jul-2017 Dividend(%) 80
Announcement Date 20-Jul-2016 Ex Dividend Date 20-Jul-2016 Dividend(%) 10
Announcement Date 17-Mar-2016 Ex Dividend Date 17-Mar-2016 Dividend(%) 70
Announcement Date 21-Jul-2015 Ex Dividend Date 21-Jul-2015 Dividend(%) 80
Announcement Date 21-Jul-2014 Ex Dividend Date 21-Jul-2014 Dividend(%) 70
Announcement Date 19-Jul-2013 Ex Dividend Date 19-Jul-2013 Dividend(%) 55
Announcement Date 20-Jul-2012 Ex Dividend Date 20-Jul-2012 Dividend(%) 55
Announcement Date 19-Jul-2011 Ex Dividend Date 19-Jul-2011 Dividend(%) 80
Announcement Date 13-Jul-2010 Ex Dividend Date 13-Jul-2010 Dividend(%) 70
Announcement Date 09-Sep-2009 Ex Dividend Date 09-Sep-2009 Dividend(%) 20
Announcement Date 11-Dec-2008 Ex Dividend Date 11-Dec-2008 Dividend(%) 33
Announcement Date 19-Sep-2008 Ex Dividend Date 19-Sep-2008 Dividend(%) 50
Announcement Date 13-Dec-2007 Ex Dividend Date 13-Dec-2007 Dividend(%) 65
Bonus
Record Date 17-May-2012 Ex-Bonus Date 17-May-2012 Ratio 1:2
Splits
Record Date 19-May-2012 Split Date 17-May-2012 Face Value (Before/After) 10.00/2.00
Others
Rights No Rights has been declared by INDOCO
Indoco Remedies Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Indoco Remedies Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Indoco Remedies Ltd's relative performance and valuation against major competitors.
Stock Name SMS Pharmaceuticals Ltd ₹281.90 (-0.70%) M. Cap (Cr) 26.40 1 Yr Return (%) +17.80% P/E (TTM) 29.62 PB Ratio 4.43
Stock Name Solara Active Pharma Sciences Ltd ₹547.70 (-2.73%) M. Cap (Cr) 19.81 1 Yr Return (%) -28.07% P/E (TTM) 380.12 PB Ratio 2.23
Stock Name Morepen Laboratories Ltd ₹44.01 (-1.83%) M. Cap (Cr) 24.12 1 Yr Return (%) -39.90% P/E (TTM) 24.45 PB Ratio 2.09
Stock Name Indoco Remedies Ltd ₹257.25 (+2.06%) M. Cap (Cr) 23.73 1 Yr Return (%) -14.19% P/E (TTM) -21.48 PB Ratio 2.18
Stock Name Novartis India Ltd ₹672.25 (-2.48%) M. Cap (Cr) 16.60 1 Yr Return (%) -1.49% P/E (TTM) 19.25 PB Ratio 2.81
Stock Name Amrutanjan Health Care Ltd ₹696.00 (-0.69%) M. Cap (Cr) 20.12 1 Yr Return (%) -1.35% P/E (TTM) 35.49 PB Ratio 6.16
Stock Name Shukra Pharmaceuticals Ltd ₹40.89 (-1.99%) M. Cap (Cr) 17.90 1 Yr Return (%) +601.37% P/E (TTM) 149.73 PB Ratio 32.98
Indoco Remedies Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Indoco Remedies Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 90.77 Mar 2024 176.78 Mar 2023 175.59 Mar 2022 173.55 Mar 2021 82.17
PARTICULARS Investing Activities Mar 2025 -259.79 Mar 2024 -301.70 Mar 2023 -205.31 Mar 2022 -121.41 Mar 2021 -66.70
PARTICULARS Financing Activities Mar 2025 168.62 Mar 2024 122.40 Mar 2023 22.81 Mar 2022 -44.37 Mar 2021 -29.83
PARTICULARS Net Cash Flow Mar 2025 -0.41 Mar 2024 -2.52 Mar 2023 -6.91 Mar 2022 7.77 Mar 2021 -14.35
Indoco Remedies Ltd Shareholding Pattern
This shows the ownership breakdown of Indoco Remedies Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 58.9%
Public 21.6%
Other Institutions 0.58%
FII 1.25%
Mutual Funds 17.58%
About Indoco Remedies Ltd
Indoco Remedies Limited, incorporated on August 23, 1947 is a Mumbai-based pharmaceutical company focused on formulations, with some presence in contract manufacturing and research. The Company headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). Indoco, a USD 212 million company has 11 manufacturing facilities, 7 of which are for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility.Currently, Indoco has a presence in therapeutic segments including anti-infective, anti-cold preparation, opthalmic, antispasmodic, stomatology, anti-inflammatory and anti-fungal. As per AC Nielsen ORG-MARG market survey (August 2004) of doctors, Indoco ranked first in the stomatology, ninth in the opthalmic and twelve in the pediatric segments in terms of prescription generation in the domestic market. In the overall pharma industry, Indoco is ranked 34th as per AC Nielsen ORG-MARG Retail Audit, but ranked 23rd in terms of prescription generation, indicating the strength of its marketing network. Further, the company last year launched a new super specialty division, with focus on diabetic and cardio-vascular segments. Its entry into the lifestyle segment with a strong presence in the prescription segment would augur well for the higher- than-average industry growth. Currently, Indoco has 4 manufacturing facilities. Two are located in Mumbai and two in Goa, and an R&D centre in Mumbai. The solid dosage facility in Goa has been accredited by UK-Medicines and Healthcare Products Regulatory Agency (MHRA), and the sterile plant of Goa has been designed as per US Food and Drug Administration (FDA) norms. On the selling front, it has a marketing network of 1,248 medical representatives.In July 2014, the Company purchased the remaining shares of its subsidiary, Xtend Industrial Designers and Engineers Private Limited to make it a 100% subsidiary of the Company.In April 2015, the Company acquired from Piramal Enterprise Limited, their Clinical Research Division, located in Hyderabad. The division is equipped with a 98-bed facility, including a four-bed ICU, state-of-the-art analytical lab and capabilities of eCTD submission. It also has GCP certification from UK-MHRA and also has regulatory approvals from several bodies including USFDA. The acquisition would reduce the Company's dependability to outsource bio-equivalence studies. This will not only reduce cost but also ensure time-bound outcome of studies and add pace to the Company's existing R&D efforts.In December, 2015, the Company incorporated Indoco Remedies Singapore Pte Limited, a 100% subsidiary. The subsidiary will be used for the expansion of the company's ambitious plans to extend its activities in the European and US markets. The company has the following 3 subsidiary companies as on 31 March 2016.i. Xtend Industrial Designers and Engineers Private Limited,ii. Indoco Pharmchem Limited,iii. Indoco Remedies Singapore Pte. Ltd.During the year 2017-18, the Company (F&D) was granted two patents by the Indian Patent Office and one by United States Patents Office for formulation of Olopatadine, Gliclazide, and Brinzolamide respectively. The Company was also granted three patents by Indian Patents Office for manufacturing processes of three APIs, viz., Febuxostat, Rufinamide and Lacosamide.Indoco's R&D efforts received due recognition with the `Best Process Patent Award for the year 2016-2017' forfive Indian patents granted related to `Processforthe preparation of Tapentadol', `Process for the preparation of Aminoindane compound', `Process for preparation of Pyrazole derivatives', `Preparation of phenylacetic acid derivative' and `Preparation of Substituted 1H-imidazo[4,5-c] quinoline'. This award was presented at Indian Drug Manufacturers Association's 56th Annual Day celebrations held on 20 January 2018.100% subsidiary known as Indoco Remedies Singapore Pte Ltd. was set up in the Czech Republic effective from April 9, 2019.In August'21, Company received GCP & GLP Accreditation from the UK-MHRA (Medicines and Healthcare Products Regulatory Agency) for its Clinical Research Division - AnaCipher, located at Hyderabad. The Company launched six new products (SKUs), two in the acute segment, Naricover and Dropizin Syrup, one in the chronic segment, Methycal 60 K and three in the sub-chronic segment, Rexidin SRS, Noxa and Subitral in the domestic market in 2022. In 2023, Company acquired 85% equity stake in the US based FPP Holding Company, LLC for USD 4 million from Contract Pharmacal Corp. (CPC). Warren Remedies Private Limited a wholly owned subsidiary of the Company, was incorporated in 2022-23 for setting up a unit for manufacturing of pharmaceutical products both formulations as well as Active Pharmaceutical Ingredients (API). The Company acquired 26% equity stake each in Kanakal Wind Energy Private Limited and Jalansar Wind Energy Private Limited, representing 8,64,000 equity shares of Rs 10/- each and 5,76,000 equity shares of Rs 10/- each respectively, for setting up Solar Power Plant at Akkalkot, Solapur District, Maharashtra.
Chairman (Non-Executive)
Suresh G Kare
Registered office Indoco House 166 C S T Road, Santacruz (East) Kalina, Mumbai, Maharashtra, 400098
FAX :91-022-26541851-55
Background
Incorporation Year 1947
Face Value ₹2.00
Market Lot 1
FAQs on Indoco Remedies Ltd
How to buy Indoco Remedies Ltd shares on NSE?
To buy Indoco Remedies Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Indoco Remedies Ltd share price today?
The Indoco Remedies Ltd share price on NSE is ₹257.25 today.
What is the market cap of Indoco Remedies Ltd on NSE?
The company has a market capitalization of ₹2373.08.
What is the PE & PB ratio of Indoco Remedies Ltd?
PE is -21 and PB is -12.
What is the 52 Week High and Low of Indoco Remedies Ltd shares?
Indoco Remedies Ltd stock price high: ₹355 Indoco Remedies Ltd stock price low: ₹190.